Targeting specific genetic weaknesses in kidney cancer
Official title: Synthetic Lethal Targeting of SETD2 in Renal Cell Carcinoma
Funded at Mayo Clinic Rochester · NIH-11005208 · Data updated 2026-11-12
This study is looking at how specific genetic changes in clear cell kidney cancer can be targeted to create better treatments, especially focusing on a gene called SETD2 that is important for patient outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | February 1, 2023 |
| Project end | January 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $539,540 |
| NIH project number | 5R01CA271503-03 |
| Project ID | NIH-11005208 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with clear cell renal cell carcinoma who have specific genetic mutations, particularly in the SETD2 gene.
✕Less likely to help
Patients with renal cell carcinoma that does not have actionable mutations or those with other types of kidney cancer may not benefit from this research.
What this research studies
This research investigates how certain genetic mutations in clear cell renal cell carcinoma (ccRCC) can be targeted for treatment. It focuses on the loss of the SETD2 gene, which is linked to poor outcomes in patients. By using advanced techniques like CRISPR/Cas9, the study aims to identify vulnerabilities in cancer cells that can be exploited for therapeutic purposes. The goal is to develop new treatment strategies that specifically address these genetic weaknesses, potentially improving patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for patients with clear cell renal cell carcinoma, improving survival rates and treatment efficacy.
How similar studies have gone: Other research has shown promise in targeting genetic vulnerabilities in cancer, making this approach both innovative and grounded in previous successes.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Robertson, Keith D — Mayo Clinic Rochester
- Study coordinator: Robertson, Keith D
Related research
Other NIH-funded projects on the same topics.
-
Understanding how kidney cancer spreads to bone and how to fight it
A patient-focused look at how clear cell renal cell carcinoma spreads to bone and how new treatments might help people with advanced disease.
-
Improve precision medicine for kidney cancer in people of African descent
A research project will explore why kidney cancer affects people of African ancestry differently and how to use genomics to guide better treatments.
-
Engineering immunogenic cell death to boost melanoma and kidney cancer therapy
This grant supports research aimed at making melanoma and kidney cancer cells die in a way that triggers a stronger immune response in patients.
-
Prognostic test to predict metastasis in clear cell kidney cancer
A new 12-marker biomarker test for people with clear cell renal cell carcinoma may help doctors predict which patients are at higher risk of metastasis.
-
Defining metabolic targets in kidney cancer for new treatments
A cancer-focused project is exploring how kidney cancer uses metabolism so doctors can find new, targeted ways to treat it.
-
Targeting HIF2 in kidney cancer: a new approach for clear cell RCC
A kidney cancer research program tests whether blocking HIF2 can slow or stop tumors in people with clear cell renal cell carcinoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.